A novel mechanism of action natural product for treatment of drug-resistant gonorrhea

Ended Project Grant Awarded Last action

Award ID
R43AI174490
Recipient
Awarding agency
Obligated
$872,444

Award facts

Assistance listing
93.855 Allergy and Infectious Diseases Research
Completion date
Originally
Place of performance
Huntsville, AL 35806, USA

Award details come from USAspending.gov.

Description

As the agency reported it.

Abstract
This project seeks to develop a new class of antibiotics against neisseria gonorrhoeae (NG). NG is considered to be of the highest threat level by the CDC due to its propensity to rapidly develop drug resistance. CFD research has discovered a novel natural product (NP) with potent NG activity, which we seek to develop here. Aim 1 will build on our established medicinal chemistry program to diversify and optimize the NP's scaffold for improved potency, cytotoxicity and drug-like properties. Aim 2 will test the in vivo efficacy of the best analogues from aim 1 in an established mouse model of NG infection. During phase II, these data will drive further medicinal chemistry design and synthesis of a lead series. Mechanism of action will be elucidated. Followed by in vivo toxicity, and pharmacokinetics to produce an optimized lead compound for further preclinical development as a novel NG antibiotic.

Transactions

Action Obligated Date
Amendment $0
Amendment $289,050
Amendment $291,697
Original award $291,697

Quick answers

Who received award R43AI174490?

R43AI174490 was awarded to CFD Research Corporation by National Institute of Allergy and Infectious Diseases (National Institutes of Health) on April 18, 2024.

How much is award R43AI174490 worth?

$872,444 has been obligated on R43AI174490.

On GovTribe

See this award's full record

  • Every transaction and subaward
  • The recipient's other awards and teaming partners
  • Similar grant awards
  • Ask GovTribe AI about this award
Try for free Login